249 related articles for article (PubMed ID: 15253730)
1. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.
Gouva C; Nikolopoulos P; Ioannidis JP; Siamopoulos KC
Kidney Int; 2004 Aug; 66(2):753-60. PubMed ID: 15253730
[TBL] [Abstract][Full Text] [Related]
2. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
3. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
4. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
5. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
7. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
8. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients.
Nephron; 1992; 61(4):399-403. PubMed ID: 1501735
[TBL] [Abstract][Full Text] [Related]
13. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
Locatelli F; Olivares J; Walker R; Wilkie M; Jenkins B; Dewey C; Gray SJ;
Kidney Int; 2001 Aug; 60(2):741-7. PubMed ID: 11473657
[TBL] [Abstract][Full Text] [Related]
14. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients.
Noshad H
Iran J Kidney Dis; 2013 May; 7(3):220-5. PubMed ID: 23689155
[TBL] [Abstract][Full Text] [Related]
16. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
17. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure.
Di Iorio BR; Minutolo R; De Nicola L; Bellizzi V; Catapano F; Iodice C; Rubino R; Conte G
Kidney Int; 2003 Nov; 64(5):1822-8. PubMed ID: 14531817
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease.
Dean BB; Dylan M; Gano A; Knight K; Ofman JJ; Levine BS
Curr Med Res Opin; 2005 Jul; 21(7):981-7. PubMed ID: 16004664
[TBL] [Abstract][Full Text] [Related]
20. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
